Table 2 List of all drug synergisms
From: Predicting and characterizing selective multiple drug treatments for metabolicdiseases and cancer
Drugs | Side eff. | Syn. | ratio | Class |
|---|---|---|---|---|
Rosiglitazone (# 7) - Quinacrine (# 36) -Cerulenin (# 62) - Tyloxapol (# 85) | 363.8 | 91 | 25.0% | A |
Rosiglitazone (# 7) - Quinacrine (# 36) - Orlistat(# 65) - Tyloxapol (# 85) | 377.7 | 91 | 24.0% | A |
Rosiglitazone (# 7) - Indomethacin (# 22) - Cerulenin (# 62)- Tyloxapol (# 85) | 390.6 | 91 | 23.2% | A |
Rosiglitazone (# 7) - Diclofenac (# 35) -Cerulenin (# 62) - Tyloxapol (# 85) | 397.5 | 91 | 22.8% | A |
Rosiglitazone (# 7) - Indomethacin (# 22) - Orlistat(# 65) - Tyloxapol (# 85) | 404.5 | 91 | 22.4% | A |
Rosiglitazone (# 7) - Diclofenac (# 35) - Orlistat(# 65) - Tyloxapol (# 85) | 411.4 | 91 | 22.1% | A |
Rosiglitazone (# 7) - Cerulenin (# 62) | 298.9 | 52 | 17.3% | A |
Rosiglitazone (# 7) - Orlistat (# 65) - | 312.8 | 52 | 16.6% | A |
Indomethacin (# 22) - Fomepizole (# 75) | 84.7 | 1 | 1.1% | B |
Naftifine (# 43) - Acetylsalicylic acid (# 55) | 116.0 | 6 | 5.1% | C |
Acetylsalicylic acid (# 55) - Tioconazole (# 60) | 116.0 | 6 | 5.1% | C |
Simvastatin/Pravastatin (# 4) - Acetylsalicylicacid (# 55) | 123.9 | 6 | 4.8% | C |
Rosiglitazone (# 7) - Tioconazole (# 60) | 280.9 | 6 | 2.1% | C |
Rosiglitazone (# 7) - Naftifine (# 43) | 280.9 | 6 | 2.1% | C |
Simvastatin/Pravastatin (# 4) - Rosiglitazone(# 7) | 288.8 | 6 | 2.0% | C |
Carbidopa (# 6) - Droxidopa (# 24) | 93.1 | 1 | 1.0% | D |
Droxidopa (# 24) - Selegiline (# 45) | 96.1 | 1 | 1.0% | D |
Droxidopa (# 24) - Minaprine (# 49) | 152.4 | 1 | 0.6% | D |
Droxidopa (# 24) - Zonisamide (# 54) | 289.7 | 1 | 0.3% | D |
Mycophenolic acid (# 42) - Mercaptopurine (# 58) | 11.0 | 5 | 45.4% | E |
Ribavirin (# 51) - Mercaptopurine (# 58) | 23.9 | 5 | 20.9% | E |
Udenafil (# 10) - Mycophenolic acid (# 42) -Mercaptopurine (# 58) - | 18.0 | 7 | 38.8% | E |
Mycophenolic acid (# 42) - Dipyridamole (# 57) -Mercaptopurine (# 58) | 22.0 | 7 | 31.8% | E |
Udenafil (# 10) - Ribavirin (# 51) - Mercaptopurine(# 58) | 30.9 | 7 | 22.6% | E |
Ribavirin (# 51) - Dipyridamole (# 57) -Mercaptopurine (# 58) | 34.9 | 7 | 20,0% | E |
Theophylline (# 18) - Mycophenolic acid (# 42) -Mercaptopurine (# 58) | 41.7 | 7 | 16.7% | E |
Mycophenolic acid (# 42) - Pentoxifylline (# 50) -Mercaptopurine (# 58) | 53.8 | 7 | 13.0% | E |
Theophylline (# 18) - Ribavirin (# 51) -Mercaptopurine (# 58) | 54.6 | 6 | 10.9% | E |
Pentoxifylline (# 50) - Ribavirin (# 51) -Mercaptopurine (# 58) | 66.7 | 6 | 8.9% | E |
Pentoxifylline (# 50) - Arsenic trioxide (# 72) | 118.2 | 17 | 14.3% | F |
Cladribirne (# 16) - Pentoxifylline (# 50) | 118.2 | 17 | 14.3% | F |
Gemcitabine (# 30) - Pentoxifylline (# 50) | 157.8 | 15 | 9.5% | F |